{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:29:39Z","timestamp":1761964179790},"reference-count":54,"publisher":"Wiley","issue":"8b","license":[{"start":{"date-parts":[[2008,7,9]],"date-time":"2008-07-09T00:00:00Z","timestamp":1215561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cellular Molecular Medi"],"published-print":{"date-parts":[[2009,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The ability of IL\u201012 to initiate anti\u2010leukaemia immune responses has been well established; however clinical outcomes fail to recapitulate the therapeutic benefits observed in the laboratory. To address this, we compared two systems of IL\u201012 therapy that elicit protective immune responses against the murine acute lymphoblastic leukaemia (ALL) cell line, 70Z\/3. These systems differ in the method of IL\u201012 administration and ultimately result in leukaemia clearance by distinct mechanisms, emphasizing the importance of treatment vehicle. Injecting low\u2010dose IL\u201012 was sufficient to elicit long\u2010term protective immunity against an established leukaemia burden, mediated by both CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> T cells. These findings agree with the standard model of IL\u201012 activity. We compared this protocol to a cell\u2010based approach in which a novel lentiviral vector (LV) expressing murine IL\u201012 was created, 70Z\/3 cells transduced, and clones selected that stably secrete different amounts of IL\u201012. We found that only a small proportion (1%) of IL\u201012 secreting cells were required for rejection but that the amount of IL\u201012 produced per cell was critical for successful therapy. Importantly, the levels of IL\u201012 required were found to be higher than the levels reported to date in the human clinical trial literature. We found that the cell\u2010based approach led to protective immunity that was both long\u2010term and specific but dependent primarily on a CD4<jats:sup>+<\/jats:sup> cellular subset alone. Our results highlight that the mode of IL\u201012 delivery has a distinct impact on the immune response initiated, leading to leukaemia clearance by disparate mechanisms. We also establish a new and critical parameter, IL\u201012 production\/cell, which may have significant implications for future therapeutic design.<\/jats:p>","DOI":"10.1111\/j.1582-4934.2008.00412.x","type":"journal-article","created":{"date-parts":[[2008,7,8]],"date-time":"2008-07-08T09:51:26Z","timestamp":1215510686000},"page":"1962-1976","source":"Crossref","is-referenced-by-count":19,"title":["IL\u201012 immunotherapy of murine leukaemia: comparison of systemic <i>versus<\/i> gene modified cell therapy"],"prefix":"10.1111","volume":"13","author":[{"given":"Alain","family":"Labbe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Nelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagdeep","family":"Walia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lintao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caren","family":"Furlonger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Medin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Paige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2004.03.002"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/145749690409300212"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(03)00210-4"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-002-0356-5"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1998.00702.x"},{"key":"e_1_2_6_7_2","first-page":"76","article-title":"Repeated administrations of interleukin (IL)\u201012 are associated with persistently elevated plasma levels of IL\u201010 and declining IFN\u2010gamma, tumor necrosis factor\u2010alpha, IL\u20106, and IL\u20108 responses","volume":"9","author":"Portielje JE","year":"2003","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.11.4473"},{"key":"e_1_2_6_9_2","first-page":"2541","article-title":"Effects of single\u2010dose interleukin\u201012 exposure on interleukin\u201012\u2010associated toxicity and interferon\u2010gamma production","volume":"90","author":"Leonard JP","year":"1997","journal-title":"Blood."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-003-0381-z"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980831)77:5<720::AID-IJC10>3.0.CO;2-5"},{"key":"e_1_2_6_12_2","first-page":"7563","article-title":"Administration of interleukin\u201012 enhances the therapeutic efficacy of dendritic cell\u2010based tumor vaccines in mouse hepatocellular carcinoma","volume":"61","author":"Tatsumi T","year":"2001","journal-title":"Cancer Res."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.153.4.1697"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65373-4"},{"key":"e_1_2_6_15_2","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins MB","year":"1997","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_16_2","first-page":"3686","article-title":"Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma","volume":"8","author":"Lenzi R","year":"2002","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/107999001750169934"},{"key":"e_1_2_6_18_2","first-page":"1678","article-title":"Phase I trial of twice\u2010weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN\u2010gamma induction is associated with clinical response","volume":"6","author":"Gollob JA","year":"2000","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_19_2","first-page":"2460","article-title":"The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12","volume":"57","author":"Coughlin CM","year":"1997","journal-title":"Cancer Res."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010101)91:1<113::AID-CNCR15>3.0.CO;2-7"},{"key":"e_1_2_6_21_2","first-page":"7","article-title":"Two phase I studies of low dose recombinant human IL\u201012 with Melan\u2010A and influenza peptides in subjects with advanced malignant melanoma","volume":"3","author":"Cebon J","year":"2003","journal-title":"Cancer Immunol."},{"key":"e_1_2_6_22_2","first-page":"182","article-title":"Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo","volume":"54","author":"Tahara H","year":"1994","journal-title":"Cancer Res."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.154.12.6466"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.155.3.1393"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700013"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/104303401300057388"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402590"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.463"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603857"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302941"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00304.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/14653240701589221"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.9.5354"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.121.2.641"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0407572101"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.11.8463-8471.1998"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0028"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1006\/taap.2001.9298"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(04)00026-2"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1053\/jpsu.2003.50043"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.045"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.12.7288"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1555"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0121"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-5-18"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1845"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.25.14730"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050162"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.05.011"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05843.x"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.02.003"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.8.5668"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxl132"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051318"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-061309"}],"container-title":["Journal of Cellular and Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1582-4934.2008.00412.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1582-4934.2008.00412.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/j.1582-4934.2008.00412.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1582-4934.2008.00412.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T17:07:04Z","timestamp":1692724024000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1582-4934.2008.00412.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,9]]},"references-count":54,"journal-issue":{"issue":"8b","published-print":{"date-parts":[[2009,8,2]]}},"alternative-id":["10.1111\/j.1582-4934.2008.00412.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1582-4934.2008.00412.x","archive":["Portico"],"relation":{},"ISSN":["1582-1838","1582-4934"],"issn-type":[{"value":"1582-1838","type":"print"},{"value":"1582-4934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,9]]}}}